Google Translate Disclaimer

A number of pages on the Government of Saskatchewan's website have been professionally translated in French. These translations are identified by a yellow box in the right or left rail that resembles the link below. The home page for French-language content on this site can be found at:

Renseignements en Français

Where an official translation is not available, Google™ Translate can be used. Google™ Translate is a free online language translation service that can translate text and web pages into different languages. Translations are made available to increase access to Government of Saskatchewan content for populations whose first language is not English.

Software-based translations do not approach the fluency of a native speaker or possess the skill of a professional translator. The translation should not be considered exact, and may include incorrect or offensive language. The Government of Saskatchewan does not warrant the accuracy, reliability or timeliness of any information translated by this system. Some files or items cannot be translated, including graphs, photos and other file formats such as portable document formats (PDFs).

Any person or entities that rely on information obtained from the system does so at his or her own risk. Government of Saskatchewan is not responsible for any damage or issues that may possibly result from using translated website content. If you have any questions about Google™ Translate, please visit: Google™ Translate FAQs.

DRUG PLAN EXPANDS LIST OF COVERED DRUGS IN 1999

Released on January 17, 2000

Saskatchewan's Drug Plan has expanded its coverage over the past year to

include more than two dozen new drugs.



Twenty seven new drugs to help people with conditions ranging from arthritis to

asthma were approved for coverage under the Drug Plan in 1999. In addition, 68

new generic drugs—lower cost replicas of name brand drugs—were approved.



"Our independent drug review committees looked at all of these drugs to

determine those that have proven benefits for people and the greatest value to

health care," Associate Minister of Health Judy Junor said. "We are pleased to

be able to help provide these many new treatments which can help improve the

health and well being of our citizens."



The list of new drugs includes Celebrex, a breakthrough treatment for

arthritis, Rebetron, a new treatment for hepatitis, and Accolate and Singulair,

treatments for asthma.



The Saskatchewan Prescription Drug Plan now covers more than 3,000 products and

assists more than 100,000 families with the cost of drugs. Last year,

Saskatchewan people filled more than 6.6 million prescriptions. To keep pace

with the growing numbers of prescriptions and the rising cost of drugs, the

Drug Plan budget grew to $77.8 million in 1999/2000, up 21.5 per cent from the

previous year.



Another 10 new drugs were reviewed and not approved for coverage in 1999.

Drugs are not approved when the clinical results are uncertain or the benefits

of the drug are not considered sufficient to warrant coverage.



Junor noted that 16 additional drugs are currently under review and dozens more

will likely be submitted by manufacturers in the coming year. Two expert

committees review each drug to determine its medical benefits, cost and overall

value to health care before making recommendations to the minister. "I want to

commend our committee members for their hard work over the past year in helping

us find the best ways to help meet the health care needs of our citizens,"

Junor said.



-30-



For more information, contact:



Jeff Brown

Saskatchewan Health

Communications Branch

Regina

Phone: (306) 787-4088

We need your feedback to improve saskatchewan.ca. Help us improve